Dr. Barry Davis, a professor in the department of biostatistics at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, has been elected a member of the International Statistical Institute (ISI).
The ISI is one of the oldest international scientific associations functioning in the modern world. Its first congresses were convened in 1853 and it was formally established in 1885. The Institute is an autonomous society which seeks to develop and improve statistical methods and their application through the promotion of international activity and cooperation.
Dr. Davis, a biostatistician, led a landmark study of blood pressure medications, which found that diuretics or water pills matched or outperformed higher priced medications. More than 42,000 people participated in the study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Dr. Davis’s most recent work has involved a randomized controlled clinical trial comparing standard sickle cell anemia therapy to an alternative therapy of hydroxyurea in pediatric patients, called Trans-Cranial Doppler (TCD) With Transfusions Changing to Hydroxyurea (TWiTCH).
Dr. Davis holds the Guy S. Parcel Chair in Public Health and serves as director of the Coordinating Center for Clinical Trials at UTHealth School of Public Health. He received his medical degree at University of California, San Diego, and his doctorate degree at Brown University.
Dr. Davis is a fellow of the American Statistical Association, the American Heart Association, the American College of Preventive Medicine, the Society of Clinical Trials and the American Association for the Advancement of Science. His research focuses on theory and practice of clinical trials.